There is no permanent cure for either Type 1 or Type 2 diabetes today. But for Type 2, remission is a realistic possibility through sustained weight loss, dietary changes, or surgery. For Type 1, experimental therapies like islet cell transplantation can eliminate the need for insulin injections in some people, though they come with significant trade-offs. Roughly 589 million adults worldwide live with diabetes, and that number is projected to reach 853 million by 2050, making the distinction between “cure” and “remission” more than academic.
Why Doctors Say “Remission,” Not “Cure”
A consensus report from the American Diabetes Association and the European Association for the Study of Diabetes defines remission as maintaining an HbA1c below 6.5% for at least three months after stopping all diabetes medications. That threshold matters: it means your blood sugar has returned to a range that no longer meets the diagnostic criteria for diabetes, without pharmaceutical help.
The reason experts avoid the word “cure” is that diabetes can return. People who achieve remission through weight loss can lose it if the weight comes back. Islet cell transplants can fail over time. The underlying vulnerability, whether it’s autoimmune destruction of insulin-producing cells in Type 1 or insulin resistance in Type 2, doesn’t fully disappear. Remission is the honest term for what’s currently achievable.
Type 2 Remission Through Weight Loss
The strongest evidence for Type 2 remission comes from the DiRECT trial, a landmark UK study that put people with Type 2 diabetes on an intensive weight management program. At both the one-year and two-year marks, over 80% of participants who lost more than 15 kilograms (about 33 pounds) were in remission. Among those who lost more than 10 kilograms (22 pounds), 75% achieved remission. The pattern is clear: the more weight you lose and keep off, the better your chances.
The challenge is maintaining that loss. Five-year follow-up data from the same trial showed that remission rates declined as participants regained weight over time. This doesn’t mean the effort is wasted. Even partial weight loss improves blood sugar control, reduces cardiovascular risk, and can lower medication needs. But sustained remission requires sustained lifestyle change.
Low-Carb Diets as a Path to Remission
A systematic review published in The BMJ pooled data from randomized trials comparing low-carbohydrate diets to standard diets for people with Type 2 diabetes. At six months, 57% of people on low-carb diets achieved an HbA1c below 6.5%, compared with 31% on control diets. They also lost an average of 3.5 kilograms more than the control groups and saw larger drops in fasting blood sugar.
The picture gets more complicated at 12 months. The advantage in HbA1c shrank by about half, weight loss differences became negligible, and remission data were sparse. When remission was defined strictly as normal HbA1c plus no diabetes medication, the benefit at six months was small. People already using insulin saw fewer remissions than those who weren’t, suggesting that low-carb diets work best earlier in the disease process, before insulin-producing cells are severely depleted.
The takeaway: a low-carb diet can be an effective tool for achieving remission in Type 2 diabetes, particularly in the first six months and for people not yet on insulin. But like weight loss more broadly, the benefits depend on whether you can sustain the dietary change long-term.
Bariatric Surgery and Type 2 Remission
Bariatric surgery produces the most dramatic remission rates, especially for people with obesity. Even among patients who have had Type 2 diabetes for 10 years or longer, about two-thirds achieve remission within the first year after surgery. However, that rate drops by roughly 10 percentage points each year afterward: 66% at one year, 54% at two years, 42% at three years.
Surgery changes more than just body weight. It alters gut hormones, bile acid signaling, and the way your body processes nutrients, which helps explain why blood sugar often improves within days, before significant weight loss has occurred. Still, the declining remission rates over time reinforce the same lesson: diabetes has a persistent biological basis that can reassert itself.
Type 1: Islet Cell Transplantation
Type 1 diabetes is an autoimmune condition where the body destroys its own insulin-producing beta cells. Because the root cause is an immune system problem rather than a metabolic one, weight loss and diet can’t produce remission. The closest thing to a cure involves replacing the destroyed cells.
Islet cell transplantation takes insulin-producing cell clusters from a donor pancreas and infuses them into the recipient’s liver. In the most rigorous clinical trials, 52% of recipients were insulin-independent at one year, and 87.5% achieved good blood sugar control without dangerous low-blood-sugar episodes. Among those who did become insulin-independent, more than half maintained that status over a median follow-up of 5.5 years.
The catch is significant. Recipients need lifelong immunosuppressive drugs to prevent their body from rejecting the transplanted cells, and those drugs carry their own risks, including increased susceptibility to infections and certain cancers. The procedure typically requires cells from two donor pancreases, and donor organs are scarce. For now, islet transplantation is reserved for people with severe, life-threatening hypoglycemia that can’t be managed any other way.
Delaying Type 1 With Immunotherapy
For people identified as high-risk for Type 1 (through screening for autoantibodies), a drug called teplizumab can delay the onset of clinical diabetes. In a pivotal trial conducted by TrialNet, the median time to diagnosis was about five years in the treatment group, compared with 2.3 years in the placebo group. That’s roughly a two-and-a-half-year delay.
This isn’t a cure or even remission. It’s a postponement. But for a child or young adult facing a lifetime of insulin management, an extra two or more years without the disease has real value. It’s also the first drug ever approved specifically to delay any autoimmune disease, which marks a shift in how researchers think about intervening in Type 1.
Experimental Approaches on the Horizon
The most ambitious research aims to solve the immune problem at its source. Scientists are adapting CAR-T cell therapy, a technique originally developed to fight blood cancers, for use in Type 1 diabetes. Instead of engineering immune cells to attack tumors, the goal is to create specialized regulatory immune cells (CAR Tregs) that can suppress the specific immune response destroying beta cells. Early studies in lab and animal models have shown promising results with both beta-cell-specific and insulin-specific versions of these engineered cells, but this work has not yet reached large-scale human trials.
Stem cell-derived beta cells represent another active area. If researchers can grow unlimited insulin-producing cells in a lab and protect them from immune attack, that would solve both the supply problem and the rejection problem that limit islet transplantation. Several companies have early-stage trials underway, but no product is close to widespread availability.
Technology That Functions Like a Cure
While a true cure remains elusive for Type 1, closed-loop insulin delivery systems (often called artificial pancreas systems) are narrowing the gap between living with diabetes and living without it. These systems combine a continuous glucose monitor with an insulin pump and an algorithm that automatically adjusts insulin delivery throughout the day.
A meta-analysis found that people using closed-loop systems spent about 10 percentage points more time with blood sugar in the target range compared to standard care, while also experiencing less hypoglycemia and lowering their HbA1c by an average of 0.3%. That may sound modest, but in practical terms it means less moment-to-moment management, fewer dangerous lows overnight, and more stable blood sugar without constant manual intervention. For many people with Type 1, this technology has transformed daily life even though the underlying disease remains.